- POSITIVE
Annual Revenue Himalaya Nutravedics Mar-2026 Annual Revenue is Rs 43 Cr which is growth of 105.4% YoY.
- POSITIVE
Annual Net Profit Himalaya Nutravedics Mar-2026 Annual Net Profit is Rs 7 Cr which is growth of 231.1% YoY.
Himalaya Nutravedics India was incorporated on June 16, 2022. The company manufactures, markets and distributes Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing. Its diversified portfolio includes classical and proprietary Ayurvedic formulations and nutraceutical products in capsules, tablets, liquid orals and medicated oils
| Bidding Dates |
|---|
| 22 Sep 2026 - 24 Sep 2026 |
| Subscription |
|---|
| 2.24x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹240,000 | 2 | 2 | 1200 | 2.5 M | ₹100 - ₹106 | 68.13 % | ₹250.0 M - ₹265.0 M | RHP DOC |
Himalaya Nutravedics IPO SUBSCRIPTION STATUS
24 Sep '26Total2.24x
Retail Individual Investor2.56x
HNI (NII) Investors2.9x
Qualified Institutional Buyers1x
Himalaya Nutravedics IPO overall subscription rate was 2.24 times the total available shares
Himalaya Nutravedics IPO retail subscription rate was 2.56 times in the retail segment
Himalaya Nutravedics IPO non-institutional investor subscription rate was 2.9 times in the non-institutional investor category
Himalaya Nutravedics IPO Qualified Institutional Bidder subscription rate was 1 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
24 Sep 2026 (Day 3) | 2.56x | 2.9x | 1x |
23 Sep 2026 (Day 2) | 0.67x | 0.36x | 0x |
22 Sep 2026 (Day 1) | 0.16x | 0.1x | - |
Himalaya Nutravedics FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY26 | 43.1 | 7.4 | -3.8 | -3.9 | 18.8% |
| FY25 | 21.0 | 2.2 | -1.4 | -1.6 | 14.2% |
| FY24 | 14.4 | 0.4 | -0.6 | -1.6 | 6.5% |
Himalaya Nutravedics IPO SUBSCRIPTION STATUS DETAILS
Himalaya Nutravedics had 2.5 M shares on offer
Himalaya Nutravedics IPO offer price was in the range ₹100 - ₹106
Himalaya Nutravedics IPO minimum Investment was ₹240000
Himalaya Nutravedics IPO issue size was ₹ 250.0 M - ₹ 265.0 M
Himalaya Nutravedics had a minimum lot size of 1200 Shares per application
Himalaya Nutravedics NUMBER OF SHARES ON OFFER
Total2.5 M
Fresh Issue2.5 M
Offer for Sale0
Post Issue Promoter Holding %68.13 %
Himalaya Nutravedics IPO IMPORTANT DATES
| Issue Open Date | 22 Sep 2026 |
| Issue close Date | 24 Sep 2026 |
| Allotment Date | 25 Sep 2026 |
| Refund Date | 28 Sep 2026 |
| Demat Account Credit Date | 28 Sep 2026 |
| Listing Date | 29 Sep 2026 |
| Listing on Exchange(s) | BSE |
| Himalaya Nutravedics Allotment Status | Exchange/ Registrar |
Himalaya Nutravedics IPO subscription opened on 22 Sep 2026, and closed on 24 Sep 2026
IPO allotment for Himalaya Nutravedics was finalized on Friday, 25 Sep 2026
IPO listing for Himalaya Nutravedics was on BSE on Tuesday, 29 Sep 2026
Himalaya Nutravedics IPO LISTING GAINS
| Issue Price (adjusted) | 106.0 |
| Listing Open Price | 118.0 |
| Listing Close Price | 122.9 |
| Listing Gain% | 11.3% |
| Current Gain% | 14.0% |
Himalaya Nutravedics Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Himalaya Nutravedics India Ltd. | 120.8 | 106.4 | 14.4 | 0.1 | 2.5 | 45.1 | 30.3 | 43.1 | 105.4 | 7.4 | 231.1 | 8.4 | 231.1 |
| Sun Pharmaceutical Industries Ltd. | 1777.7 | 426529.8 | 38.9 | 7.9 | 6.9 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 45.7 | 4.9 |
| Divi's Laboratories Ltd. | 9780 | 259628.3 | 88.8 | 3.3 | 23.1 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4613.4 | 175478.9 | 82.6 | -110.5 | 10.1 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 55.8 | -0.7 |
| Laurus Labs Ltd. | 2405.5 | 129972.1 | 97 | 1 | 16.6 | 16.8 | 8.4 | 6861.3 | 22.2 | 888.8 | 148 | 24.8 | 95.9 |
| Zydus Lifesciences Ltd. | 1245.5 | 125326.4 | 27.8 | -17.9 | 4.4 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 44.9 | -1.6 |
Annual
Balance Sheet
Ratios
Cash Flow
Himalaya Nutravedics annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | Mar '26 | Mar '25 | Mar '24 |
|---|---|---|---|---|
| 43.1 | 21 | 14.4 | ||
Operating Exp. Ann. | 35 | 18 | 13.5 | |
Operating Profit Ann. | 8.1 | 3 | 0.9 | |
OPM Ann. % | 18.79% | 14.24% | 6.48% | |
| 35.6 | 18.8 | 13.8 | ||
EBITDA Ann. | 8.2 | 3 | 0.9 | |
EBITDA Ann. margin % | 18.91% | 14.24% | 6.51% | |
Interest Ann. | 0.4 | 0.3 | 0.2 | |
Depr. | 0.3 | 0.4 | 0.2 | |
PBT Ann. | 7.5 | 2.3 | 0.6 | |
Tax Ann. | 0.1 | 0 | 0.2 | |
| 7.4 | 2.2 | 0.4 | ||
Net Profit Ann. | 7.4 | 2.2 | 0.4 | |
NPM Ann. % | 17.15% | 10.62% | 2.95% | |
EPS Adj. latest Ann. | 8.4 | 2.5 | 0.5 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
105.2%
2Y CAGR
73%
Net Profit Ann.
1Y CHG
236.4%
2Y CAGR
330.1%
Operating Exp. Ann.
1Y CHG
94.4%
2Y CAGR
61%
Himalaya Nutravedics INFORMATION ON IPO ISSUE
About Himalaya Nutravedics
Himalaya Nutravedics India was incorporated on June 16, 2022. The company manufactures, markets and distributes Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing. Its diversified portfolio includes classical and proprietary Ayurvedic formulations and nutraceutical products in capsules, tablets, liquid orals and medicated oils
Object of the Issue
- Funding working capital requirements
- Investment in branding, digital marketing and sales expansion
- General corporate purposes
Himalaya Nutravedics - PROMOTERS
| Name |
|---|
| Rohit Asawa |
| Divya Asawa |
| Chanda Asawa |
| Rama Raju Penmatsa |
Himalaya Nutravedics - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Rohit Asawa | Chairman & Managing Director |
| Divya Asawa | Non- Executive Director |
| Abhisheak Dhoot | Independent Director |
| Ramya Inala | Independent Director |
Himalaya Nutravedics Book Running Lead Manager
Nirbhay Capital Services Private Limited
kunjal@nirbhaycapital.com
Himalaya Nutravedics Registrar to the Offer
KFin Technologies Limited
himalaya.ipo@kfintech.com
Himalaya Nutravedics Strengths
Integrated manufacturing facility
The company operates an integrated manufacturing facility capable of producing medicated oils, soft and hard gelatin capsules, tablets and liquid orals for Ayurvedic and nutraceutical products. This multi-dosage capability supports faster product launches, diverse customer needs and efficient utilisation of manufacturing infrastructure
Strength
Broad theraupeutic coverage
The company offers Ayurvedic and nutraceutical products across gut health, cardiac and metabolic wellness, diabetes, pain management, immunity, infertility and general wellness. Its portfolio of classical, proprietary Ayurvedic formulations and nutraceutical blends supports diverse healthcare needs and cross-selling across therapeutic areas
Strength
Practitioner-led ayurvedic product adoption
The company’s Ayurvedic and nutraceutical products have gained repeat prescriptions and re-orders through practitioner-focused marketing rather than mass advertising. Its approach uses scientific detailing, clinical data, CME programmes, medical camps and targeted engagement, helping control marketing costs while strengthening practitioner acceptance
Strength
Himalaya Nutravedics Risks
Labour intensive
The company’s labour-intensive operations employ 80 personnel and may face risks from strikes, work stoppages, wage demands or future unionisation. Labour disruptions or rising employee costs could interrupt operations and adversely affect its business, financial performance and financial condition
Risk
Competition
The company operates in a highly competitive Ayurvedic and nutraceutical industry, with established players and moderate-to-high entry barriers. Failure to innovate, differentiate products, strengthen manufacturing capabilities or respond to competitors’ pricing could limit market share, growth and profitability
Risk
Regulatory risks
The company may face higher costs and operational complexity if regulations on sourcing, testing and quality of Ayurvedic and nutraceutical raw materials become more stringent. Failure to adapt to enhanced requirements could lead to manufacturing delays, regulatory action, product recalls, reputational damage and adverse financial impact
Risk
IPO FAQs
The promoters of the company are Rohit Asawa, Divya Asawa, Chanda Asawa and Rama Raju Penmatsa.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 100.0 - 106.0.
The IPO application opens on Sep 22, 2026 and closes on Sep 24, 2026.
The minimum lot size for the IPO is 2400. The maximum lot size for the IPO is 2400.
For all category investors, the minimum application amount for this IPO is Rs. 240,000.0, the maximum value for this IPO is Rs 254,400.0.
This IPO will be allotted on Sep 25, 2026.
The refund will be credited to your account on Sep 28, 2026.
The allotted shares will be credited to your demat on Sep 28, 2026.
Himalaya Nutravedics India Ltd.’s shares listed on the stock exchanges on Sep 29, 2026.